CN117396202A - 给药方案 - Google Patents

给药方案 Download PDF

Info

Publication number
CN117396202A
CN117396202A CN202280034821.XA CN202280034821A CN117396202A CN 117396202 A CN117396202 A CN 117396202A CN 202280034821 A CN202280034821 A CN 202280034821A CN 117396202 A CN117396202 A CN 117396202A
Authority
CN
China
Prior art keywords
imatinib
administered
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034821.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·K·都德
F·霍尔卡德-波泰莱雷特
F·胡特
M·昆兰
J·扎克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN117396202A publication Critical patent/CN117396202A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280034821.XA 2021-05-11 2022-05-10 给药方案 Pending CN117396202A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
US63/187,023 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (1)

Publication Number Publication Date
CN117396202A true CN117396202A (zh) 2024-01-12

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280034821.XA Pending CN117396202A (zh) 2021-05-11 2022-05-10 给药方案

Country Status (8)

Country Link
US (1) US20240245666A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337205A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518426A (cg-RX-API-DMAC7.html)
KR (1) KR20240006600A (cg-RX-API-DMAC7.html)
CN (1) CN117396202A (cg-RX-API-DMAC7.html)
CA (1) CA3218550A1 (cg-RX-API-DMAC7.html)
IL (1) IL308095A (cg-RX-API-DMAC7.html)
WO (1) WO2022238884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310395A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
CN112110880A (zh) * 2020-09-29 2020-12-22 天津红日药业股份有限公司 雄甾烷衍生物及其制备方法与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310395A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
CN112110880A (zh) * 2020-09-29 2020-12-22 天津红日药业股份有限公司 雄甾烷衍生物及其制备方法与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JORGE CORTES,等: "Combination Therapy Using Asciminib Plus Imatinib in Patients With Chronic Myeloid Leukemia: Results From a Phase 1 Study", EHA 24TH CONGRESS,ABSTRACT S883, 13 June 2019 (2019-06-13), pages 397 *
MATTHIAS HOCH,等: "Pharmacokinetics of Asciminib When T aken With Imatinib or With Food", ACCP, vol. 11, no. 2, 5 October 2021 (2021-10-05), pages 207 *
TIMOTHY P. HUGHES,等: "Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure", NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 24, 12 December 2019 (2019-12-12), pages 2315 - 232 *
桂瑞瑞;张龚莉;宋永平;: "第58届美国血液病年会关于慢性粒细胞白血病的研究精选", 临床血液学杂志, no. 01, 31 December 2018 (2018-12-31), pages 76 - 81 *

Also Published As

Publication number Publication date
JP2024518426A (ja) 2024-05-01
US20240245666A1 (en) 2024-07-25
KR20240006600A (ko) 2024-01-15
IL308095A (en) 2023-12-01
EP4337205A1 (en) 2024-03-20
WO2022238884A1 (en) 2022-11-17
CA3218550A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
US12186316B2 (en) Pharmaceutical compositions
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20170326141A1 (en) Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
JP2022514569A (ja) 非晶質スパルセンタン組成物
EP1181935A2 (en) Agent for treating mental disorders associated with cerebrovascular disorders
US20260137638A1 (en) Stat3 inhibitors for use in the treatment of non-viral liver cancer
CA2624497C (en) Antituberculosis drug combination comprising oxazole compounds
TW201828937A (zh) 供治療重症肌無力及其他肌無力症候群之用途及組合物
US20240245666A1 (en) Dosing regimens
TW202341973A (zh) 治療性化合物、調配物、及其用途
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
KR20170117185A (ko) 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
CN119816304A (zh) Nlrp3抑制剂的给药方案
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
JP2020183415A (ja) 発泡剤を含む抗微生物組成物
CN110339195A (zh) 用于治疗胆管癌的喹啉衍生物
JP2023545367A (ja) バソプレシン受容体拮抗薬療法の副作用を管理する方法
TW201919597A (zh) 利用新斯的明(neostigmine)及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
TW201919704A (zh) 利用吡啶斯的明(pyridostigmine)及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
IL227742A (en) Plumzanil complexes, compounds containing them and their uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination